Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Leuven Research Opens New Pathway… >

Leuven Research Opens New Pathway for the Treatment of Alzheimer's Disease

Published: December 3, 2012.
Released by VIB (the Flanders Institute for Biotechnology)  

Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature Medicine.

Alzheimer's Disease

Alzheimer's Disease is the most common form of dementia in the West. The damage to memory and mental function causes one of the most terrifying clinical pictures. The current drugs for Alzheimer patients support memory for a short time, but they do not stop the death of brain cells. Recent insights have shown that Alzheimer's disease causes biochemical changes in the brain many years before the symptoms of dementia are present. It is very important to develop drugs that can be taken at this early stage in order to prevent the disease.

The ɣ-secretase complex

Many candidate drugs have an effect on the ɣ-secretase complex. This complex cuts proteins at specific sites and plays an important role in the development of amyloid plaques, a pathological hallmark in of the brains of Alzheimer patients. Aberrant and excessive cleavage of the amyloid precursor protein by the y-secretase complex results in the accumulation and deposition of the β-amyloid protein in amyloid plaques.

However, the ɣ-secretase complex is also involved in cleavage of a series of other proteins essential to life. As a result, many candidate drugs that act on the ɣ-secretase complex produce toxic side effects.

GPCRs and β-arrestin

GPCRs are a family of proteins that serve as the targets of the majority of all currently marketed drugs. The Nobel Prize in Chemistry for 2012 was awarded to Dr. Robert Lefkowitz and Dr. Brian Kobilka for their groundbreaking work in this field and the many medical applications of this knowledge. It is known that GPCRs also play a role in the development of Alzheimer's disease, but it is not yet clear how GPCRs regulate the ɣ-secretase complex.

β-arrestins are a family of proteins that classically block or limit GPCR activation; however, it has been recently appreciated that β-arrestins also have additional functions. Therefore, Amantha Thathiah set up a study under the supervision of Bart De Strooper to examine the involvement of β-arrestins in the development of Alzheimer's disease.

The scientists succeeded for the first time in demonstrating that β-arrestin 2 plays a role in regulation of the ɣ-secretase complex function and in the development of Alzheimer's disease in an Alzheimer's disease mouse model. More specifically, β-arrestin 2 interacts with two GPCRs that are known to play a role in the development of Alzheimer's disease. Moreover, expression of β-arrestin 2 is also elevated in individuals with Alzheimer's disease.

Impact of the research

This research opens a new pathway for the treatment of Alzheimer's disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. Therefore, this study provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer's disease.




The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology).

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Disease 
2/4/12 
Why 2 New Studies Represent Important Breakthrough in Alzheimer's Disease Research
Two different research groups have independently made the same important discoveries on how Alzheimer's disease spreads in the brain, …
Alzheimer 
4/4/11 
Understanding Alzheimer’s: Genetic Search Uncovers Five New Genes
A leading UK scientist's search for factors that increase the risk of developing Alzheimer's has uncovered five new genes …
Brain 
2/8/11 
Combining Brain Imaging, Genetic Analysis May Help Identify People at Early Risk of Alzheimer's
For Immediate Release – February 8, 2011 - (Toronto) – A new study from the Centre for Addiction and …
Alzheimer 
1/10/12 
Protein Changes Identified in Early-onset Alzheimer's
With a lack of effective treatments for Alzheimer's, most of us would think long and hard about whether we …
Disease 
11/8/12 
Measuring Metabolism Can Predict Alzheimer's Progress with 90% Accuracy
When it comes to Alzheimer's disease, scientists usually — and understandably — look to the brain as their first …
Genetics 
10/28/13 
International Collaboration Finds 11 New Alzheimer's Genes to Target for Drug Discovery
MIAMI -- University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's …
Alzheimer 
11/6/14 
Failed Alzheimer's Test Shows in Which Direction the Research Should Continue
Disappointing results in clinical Alzheimer's studies discourage doctors and scientists from continuing their research into ɣ-secretases and a possible …
Mice 
8/22/10 
★ 
Rheumatoid Arthritis Signaling Protein Reverses Alzheimer's Disease in Mouse Model
Tampa, FL (August 23, 2010) -- A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and …
Alzheimer 
4/9/13 
New Gene Associated with Almost Doubled Alzheimer's Risk in African-Americans
NEW YORK – African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile